AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12010361 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (3TC) treatment in the presence of M184V mutation
Number of subjects: 0
Study 12010361 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART regimens
Number of subjects: 0
Study 12010361 — intervention group
Group type: EXPERIMENTAL
Intervention: 3TC treatment
Number of subjects: 0
Study 9656043 — intervention group
Group type: EXPERIMENTAL
Intervention: Back massage (6 minutes)
Number of subjects: 69
Study 9656043 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined muscle relaxation, mental imagery, and music audiotape (7.5 minutes)
Number of subjects: 69
Study 9656043 — intervention group
Group type: COMPARATOR
Intervention: Usual nursing care (control group)
Number of subjects: 69
Study 8738667 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2 g/day
Number of subjects: 491
Study 8738667 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 3 g/day
Number of subjects: 491
Study 8738667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 491
Study 2040133 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric patients
Number of subjects: 0
Study 2040133 — intervention group
Group type: COMPARATOR
Intervention: Healthy young subjects
Number of subjects: 0
Study 2040133 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 0
Study 2040133 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric patients and healthy subjects
Number of subjects: 0
Study 7027432 — intervention group
Group type: EXPERIMENTAL
Intervention: HP 549 (isoxepac) 600 mg
Number of subjects: 12
Study 7027432 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 150 mg
Number of subjects: 12
Study 7027432 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 3 g
Number of subjects: 12
Study 31785775 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 4859
Study 31785775 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran discontinuation without switching to another oral anticoagulant
Number of subjects: 4859
Study 31785775 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran discontinuation with switching to another oral anticoagulant
Number of subjects: 4859
Study 30553687 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective referral strategy using CCTA
Number of subjects: 1631
Study 30553687 — intervention group
Group type: COMPARATOR
Intervention: Direct referral strategy using ICA
Number of subjects: 1631
Study 28229278 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3-fortified doogh (FD; containing 170 mg calcium and 500 IU/250 mL)
Number of subjects: 100
Study 28229278 — intervention group
Group type: COMPARATOR
Intervention: Plain doogh (PD; containing 170 mg calcium and no vitamin D/250 mL)
Number of subjects: 100
Study 28229278 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3-fortified doogh (FD)
Number of subjects: 100
Study 26004966 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine in tumescent solution
Number of subjects: 90
Study 26004966 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine in tumescent solution
Number of subjects: 90
Study 26004966 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine in tumescent solution
Number of subjects: 90
Study 23110508 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual exposure CsA (n=33)
Number of subjects: 75
Study 23110508 — intervention group
Group type: COMPARATOR
Intervention: Reduced exposure CsA (n=42)
Number of subjects: 75
Study 23110508 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 75
Study 21641345 — intervention group
Group type: EXPERIMENTAL
Intervention: SLV320 1.25 mg
Number of subjects: 46
Study 21641345 — intervention group
Group type: EXPERIMENTAL
Intervention: SLV320 3.75 mg
Number of subjects: 46
Study 21641345 — intervention group
Group type: EXPERIMENTAL
Intervention: SLV320 7.5 mg
Number of subjects: 46
Study 21641345 — intervention group
Group type: EXPERIMENTAL
Intervention: SLV320 15 mg
Number of subjects: 46
Study 21641345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 19458428 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerin poultice applied to the flexor digitorum profundus in the middle phalanx of the little finger (GFML)
Number of subjects: 22
Study 16293377 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational lectures (study group, n=62)
Number of subjects: 125
Study 16293377 — intervention group
Group type: COMPARATOR
Intervention: No educational lectures (control group, n=63)
Number of subjects: 125
Study 15283863 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest Pain Unit (CPU) assessment
Number of subjects: 442
Study 10930154 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal monotherapy predominantly with zidovudine (ZDV)
Number of subjects: 497
Study 10930154 — intervention group
Group type: COMPARATOR
Intervention: Prior preterm birth
Number of subjects: 497
Study 10930154 — intervention group
Group type: COMPARATOR
Intervention: Multiple gestation
Number of subjects: 497
Study 10930154 — intervention group
Group type: COMPARATOR
Intervention: Antenatal alcohol use
Number of subjects: 497
Study 10930154 — intervention group
Group type: COMPARATOR
Intervention: Antenatal diagnosis of genital herpes
Number of subjects: 497
Study 10930154 — intervention group
Group type: COMPARATOR
Intervention: Antenatal diagnosis of pre-eclampsia
Number of subjects: 497
Study 10930154 — intervention group
Group type: COMPARATOR
Intervention: Baseline HIV culture titer
Number of subjects: 497
Study 10930154 — intervention group
Group type: COMPARATOR
Intervention: Antenatal cigarette use
Number of subjects: 497
Study 1461630 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose megestrol acetate (800 mg/day)
Number of subjects: 34
Study 1461630 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose megestrol acetate (160 mg/day)
Number of subjects: 34
Study 6130082 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 462
Study 6130082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study 30618048 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making tools (SDMTs)
Number of subjects: 50
Study 30618048 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SDMT)
Number of subjects: 50
Study 28597911 — intervention group
Group type: EXPERIMENTAL
Intervention: CoE‐IS‐Rifamate (Isoniazid/Rifampin 150/300 mg)
Number of subjects: 12
Study 28597911 — intervention group
Group type: COMPARATOR
Intervention: native‐Rifamate
Number of subjects: 12
Study 26663387 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 (400 mg, n = 21)
Number of subjects: 43
Study 26663387 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 43
Study 24882155 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (1.5mg/kg)
Number of subjects: 14
Study 24882155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 24882155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40IU)
Number of subjects: 14
Study 24882155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (20IU)
Number of subjects: 14
Study 24882155 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (0.75mg/kg)
Number of subjects: 14
Study 24882155 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA
Number of subjects: 14
Study 24882155 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 14
Study 23210383 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week Matrix treatment
Number of subjects: 871
Study 23210383 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 871
Study 21030727 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonweight-bearing ankle exercises
Number of subjects: 19
Study 21030727 — intervention group
Group type: COMPARATOR
Intervention: Previous care regimen (Control)
Number of subjects: 19
Study 18595289 — intervention group
Group type: EXPERIMENTAL
Intervention: Training procedure incorporating feedback and role‐play practice
Number of subjects: 8
Study 15830647 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 16
Study 15830647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12876474 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic field emitted by mobile phones, duration of exposure not specified.
Number of subjects: 78
Study 12876474 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what intervention was used).
Number of subjects: 78
Study 10593227 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple frequency bioelectrical impedance analysis (MFBIA) using the Cole model
Number of subjects: 0
Study 10593227 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple frequency bioelectrical impedance analysis (MFBIA) using the inductor circuit model (ICM)
Number of subjects: 0
Study 10593227 — intervention group
Group type: COMPARATOR
Intervention: Analogue circuit model (not specified as intervention)
Number of subjects: 0
Study 8767244 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (5 mg)
Number of subjects: 64
Study 8767244 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (1 mg)
Number of subjects: 64
Study 8767244 — intervention group
Group type: COMPARATOR
Intervention: Control (Saline)
Number of subjects: 64
Study 8767244 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (1 mg)
Number of subjects: 64
Study 1951158 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1 g carbohydrate/kg body mass (LC)
Number of subjects: 0
Study 1951158 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.2 g carbohydrate/kg body mass (HC)
Number of subjects: 0
Study 1951158 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 0
Study 6374306 — intervention group
Group type: EXPERIMENTAL
Intervention: Formaldehyde gas (0.1, 1, and 3 ppm)
Number of subjects: 13
Study 6374306 — intervention group
Group type: COMPARATOR
Intervention: Room-air placebo
Number of subjects: 13
Study 31362189 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM)
Number of subjects: 171
Study 29860341 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone/vincristine pulse therapy during maintenance therapy in the standard risk group
Number of subjects: 0
Study 29860341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive l-asparaginase therapy in the intermediate risk group
Number of subjects: 0
Study 29860341 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine intensification in the high risk group
Number of subjects: 0
Study 26036221 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 59
Study 26036221 — intervention group
Group type: COMPARATOR
Intervention: Traditional laparoscopic cholecystectomy (TLC)
Number of subjects: 59
Study 24608864 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-PC education
Number of subjects: 64
Study 24608864 — intervention group
Group type: COMPARATOR
Intervention: Conventional education
Number of subjects: 64
Study 24608864 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Tablet-PC and Conventional)
Number of subjects: 64
Study 23308123 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly resistance training
Number of subjects: 114
Study 23308123 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly resistance training
Number of subjects: 114
Study 23308123 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly balance and tone training
Number of subjects: 114
Study 23308123 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 114
Study 21824594 — intervention group
Group type: EXPERIMENTAL
Intervention: Double contrast-enhanced ultrasound (DCUS)
Number of subjects: 162
Study 21824594 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 162
Study 19005929 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheerfulness Training
Number of subjects: 0
Study 15923407 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual combinations of HIV-1 reverse transcriptase inhibitors
Number of subjects: 0
Study 15923407 — intervention group
Group type: COMPARATOR
Intervention: Triple combinations of HIV-1 reverse transcriptase inhibitors
Number of subjects: 0
Study 12859533 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 557
Study 12859533 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A
Number of subjects: 557
Study 11094033 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol
Number of subjects: 27
Study 11094033 — intervention group
Group type: COMPARATOR
Intervention: Transdermal placebo
Number of subjects: 27
Study 11094033 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol
Number of subjects: 27
Study 11094033 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 27
Study 8853164 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac 100 mg twice daily
Number of subjects: 73
Study 8853164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 1642879 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (vinblastine, mitomycin, cisplatin, and bleomycin) and radiotherapy
Number of subjects: 90
Study 1642879 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy (cisplatin and bleomycin) and radiotherapy
Number of subjects: 90
Study 1642879 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (70 Gy)
Number of subjects: 90
Study 1642879 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 90
Study 6303264 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (0.3 to 4 mg/kg)
Number of subjects: 0
Study 31425585 — intervention group
Group type: COMPARATOR
Intervention: CSSO during creep-feeding (CF) at 80 g/d per steer
Number of subjects: 64
Study 31425585 — intervention group
Group type: COMPARATOR
Intervention: CSSO during preconditioning (PC) at 150 g/d per steer
Number of subjects: 64
Study 31425585 — intervention group
Group type: COMPARATOR
Intervention: CSSO during PC
Number of subjects: 64
Study 31425585 — intervention group
Group type: COMPARATOR
Intervention: CSSO during CF
Number of subjects: 64
Study 31425585 — intervention group
Group type: COMPARATOR
Intervention: CSSO (both CF and PC)
Number of subjects: 64
Study 29504733 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 69
Study 29504733 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 69
Study 26670991 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink
Number of subjects: 15
Study 26670991 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 15
Study 26670991 — intervention group
Group type: COMPARATOR
Intervention: Uncaffeinated energy drink
Number of subjects: 15
Study 25015021 — intervention group
Group type: EXPERIMENTAL
Intervention: YOUNG (aged 18-28 years)
Number of subjects: 12157
Study 25015021 — intervention group
Group type: COMPARATOR
Intervention: OLD (aged 49-60 years)
Number of subjects: 12157
Study 25015021 — intervention group
Group type: COMPARATOR
Intervention: BABIES (cord blood units)
Number of subjects: 12157
Study 22192060 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-based anesthesia (PR)
Number of subjects: 90
Study 22192060 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-based anesthesia (SR)
Number of subjects: 90
Study 22192060 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-propofol-based anesthesia (SPR)
Number of subjects: 90
Study 20071702 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative biliary drainage for 4 to 6 weeks, followed by surgery
Number of subjects: 202
Study 20071702 — intervention group
Group type: COMPARATOR
Intervention: Early surgery within 1 week after diagnosis
Number of subjects: 202
Study 20071702 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative biliary drainage
Number of subjects: 202
Study 20071702 — intervention group
Group type: COMPARATOR
Intervention: Early surgery
Number of subjects: 202
Study 17377256 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully immersed virtual reality (VR) environment using a head mounted display (HMD)
Number of subjects: 0
Study 17377256 — intervention group
Group type: COMPARATOR
Intervention: Partially immersed (computer screen) VR environment
Number of subjects: 0
Study 15798293 — intervention group
Group type: EXPERIMENTAL
Intervention: Infinity reference (I)
Number of subjects: 11
Study 15798293 — intervention group
Group type: EXPERIMENTAL
Intervention: Linked mastoids (L) reference
Number of subjects: 11
Study 15798293 — intervention group
Group type: EXPERIMENTAL
Intervention: Average (A) reference
Number of subjects: 11
Study 15798293 — intervention group
Group type: COMPARATOR
Intervention: M reference
Number of subjects: 11
Study 15798293 — intervention group
Group type: COMPARATOR
Intervention: L reference
Number of subjects: 11
Study 15798293 — intervention group
Group type: COMPARATOR
Intervention: A reference
Number of subjects: 11
Study 12560628 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with 0.125 percent bupivocaine and morphine after combined general‐epidural anesthesia
Number of subjects: 24
Study 12560628 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient‐controlled analgesia with morphine after general anesthesia
Number of subjects: 24
Study 9583845 — intervention group
Group type: EXPERIMENTAL
Intervention: BF+SF group (iron-fortified foods from 4 to 6 months)
Number of subjects: 164
Study 9583845 — intervention group
Group type: COMPARATOR
Intervention: EBF group (exclusively breast-fed until 6 months)
Number of subjects: 164
Study 8565975 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm underwater water-jet massage (3 times, 20 min each) during treatment week
Number of subjects: 14
Study 8565975 — intervention group
Group type: COMPARATOR
Intervention: Control week (no underwater water-jet massage)
Number of subjects: 14
Study 2168152 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-resistant mutant [SR2‐410(r)]
Number of subjects: 42
Study 2168152 — intervention group
Group type: COMPARATOR
Intervention: Wild-type HRV‐2
Number of subjects: 42
Study 2168152 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-dependent mutant [SR2‐410(d)]
Number of subjects: 42
Study 345886 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor
Number of subjects: 15
Study 345886 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study 31338998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention
Number of subjects: 2361
Study 27765696 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pyeloplasty
Number of subjects: 98
Study 27765696 — intervention group
Group type: COMPARATOR
Intervention: Open pyeloplasty
Number of subjects: 98
Study 27765696 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 98
Study 25654728 — intervention group
Group type: EXPERIMENTAL
Intervention: rh-endostatin + EC
Number of subjects: 140
Study 25654728 — intervention group
Group type: COMPARATOR
Intervention: EC
Number of subjects: 140
Study 23095977 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon atrial septostomy (BAS)
Number of subjects: 21
Study 23095977 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 21
Study 20737135 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal pelvic floor muscle exercise (PFME)
Number of subjects: 300
Study 20737135 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 300
Study 19649521 — intervention group
Group type: EXPERIMENTAL
Intervention: Crown S made via Crystaleye spectrophotometer
Number of subjects: 63
Study 19649521 — intervention group
Group type: COMPARATOR
Intervention: Crown V made via conventional visual matching
Number of subjects: 63
Study 19649521 — intervention group
Group type: COMPARATOR
Intervention: Visual evaluation by patients (Vp)
Number of subjects: 63
Study 19649521 — intervention group
Group type: COMPARATOR
Intervention: Visual evaluation by prosthodontists (Vd)
Number of subjects: 63
Study 19649521 — intervention group
Group type: COMPARATOR
Intervention: Overall visual evaluation (p and d)
Number of subjects: 63
Study 16298017 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting state
Number of subjects: 0
Study 16298017 — intervention group
Group type: COMPARATOR
Intervention: Post-meal state
Number of subjects: 0
Study 14616929 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NG methylarginine hydrochloride (L‐NMMA:546C88) 6 mg/kg
Number of subjects: 12
Study 14616929 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (0.5 microg/kg/min)
Number of subjects: 12
Study 10928154 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary immunotherapy with galactoside‐specific lectin from mistletoe (ML‐1)
Number of subjects: 0
Study 10928154 — intervention group
Group type: COMPARATOR
Intervention: Standard oncologic treatment (control group)
Number of subjects: 0
Study 8959891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (500 mg) given prior to reperfusion
Number of subjects: 0
Study 8959891 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 0
Study 1541140 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 2
Study 1541140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 2991689 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH4-9 analog (Org2766) 40 mg/day
Number of subjects: 0
Study 2991689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30685963 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulfate solution (OSS)
Number of subjects: 173
Study 30685963 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid plus polyethylene glycol (AA + PEG)
Number of subjects: 173
Study 30041183 — intervention group
Group type: EXPERIMENTAL
Intervention: LPNYL treatment (energy density of 45 J/cm2, pulse width of 35 ms, spot size of 4 mm, frequency of 1 Hz, 6 treatments with 1-week intervals)
Number of subjects: 177
Study 30041183 — intervention group
Group type: COMPARATOR
Intervention: Oral itraconazole (drug group)
Number of subjects: 177